 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...160161162163164165166167168169170...235236» |
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Journal: Spontaneous regression of pancreatic cancer with liver metastases. (Pubmed Central) - Jan 4, 2020
This is the first report in the English literature showing spontaneous regression of a PDA with liver metastases. Two possible mechanisms are proposed: antitumoral autoimmunity and tumour hypoxia related to vascular disease.
- | Avastin (bevacizumab) / Roche
New P3 trial, Metastases: FOBEAR: Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer (clinicaltrials.gov) - Jan 2, 2020
P3, N=500, Not yet recruiting, Sponsor: Yanhong Deng
- | vactosertib (TEW-7197) / National OncoVenture, Theragen Etex
Enrollment open, Combination therapy, Metastases: MP-PDAC-01: Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (clinicaltrials.gov) - Dec 29, 2019
P1b, N=36, Recruiting, Sponsor: Joon Oh Park
Two possible mechanisms are proposed: antitumoral autoimmunity and tumour hypoxia related to vascular disease. Not yet recruiting --> Recruiting
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: Changes in Body Composition During Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer. (Pubmed Central) - Dec 29, 2019
Multivariable analysis revealed that low SMR measured on a postchemotherapy CT scan (hazard ratio, HR: 0.32, 95% confidence interval, CI: 0.15-0.70, p = 0.004) and visceral fat loss of at least 46.57% (HR: 0.31, 95% CI: 0.14-0.69, p = 0.004) were independent poor prognostic factors for OS. Severe visceral fat loss during FOLFOX chemotherapy and low skeletal muscle radiodensity measured on postchemotherapy CT scans are associated with poor OS in stage III and high-risk stage II colon cancer patients.
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Journal: Synchronous recurrence of concurrent colon adenocarcinoma and dedifferentiated liposarcoma. (Pubmed Central) - Dec 26, 2019
The recurrent mesenteric tumour was subsequently resected. Although concurrent cancers have been reported, this unique case of synchronous recurrence raises interesting hypotheses regarding host-tumour interaction and immune surveillance.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: The seemingly innocuous presentation of metastatic pancreatic tail cancer: a case report. (Pubmed Central) - Dec 26, 2019
Pancreatic cancer has also been shown to be associated with certain risk factors, such as smoking, high body mass index, chronic pancreatitis, and a family history of pancreatic cancer. Thus, when patients with presentations similar to our patient's with new-onset diabetes after the age of 50, along with vague symptoms such as back or abdominal pain as well as the presence of risk factors, we suggest that it is beneficial for practitioners to maintain a high index of suspicion for pancreatic cancer.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 26, 2019
P2, N=47, Completed, Sponsor: Centre Jean Perrin
Thus, when patients with presentations similar to our patient's with new-onset diabetes after the age of 50, along with vague symptoms such as back or abdominal pain as well as the presence of risk factors, we suggest that it is beneficial for practitioners to maintain a high index of suspicion for pancreatic cancer. Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019
- | Avastin (bevacizumab) / Roche
Enrollment change, Trial termination, Combination therapy, Metastases: Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Dec 26, 2019
P2/3, N=36, Terminated, Sponsor: University of California, San Francisco
Trial completion date: Mar 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019 N=70 --> 36 | Active, not recruiting --> Terminated; Low accrual
- | Enrollment closed, Trial completion date, Metastases: GABRINOX: First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. (clinicaltrials.gov) - Dec 26, 2019
P1/2, N=60, Active, not recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
N=70 --> 36 | Active, not recruiting --> Terminated; Low accrual Recruiting --> Active, not recruiting | Trial completion date: Mar 2020 --> Dec 2021
- ||| fluorouracil / Generic mfg.
Clinical, P3 data, Journal: Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. (Pubmed Central) - Dec 25, 2019
P3
Induction with MEPFL before CCRT was tolerable and significantly improved the DFS of patients with stage IVA and IVB NPC though overall survival not improved. NCT00201396.
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 24, 2019
P2, N=83, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00201396. Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> May 2019 | Trial primary completion date: Jan 2021 --> May 2019
- ||| Lumakras (sotorasib) / Amgen
Enrollment open, Trial completion date, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Dec 23, 2019
P1b, N=120, Recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> May 2019 | Trial primary completion date: Jan 2021 --> May 2019 Not yet recruiting --> Recruiting | Trial completion date: Jul 2022 --> Dec 2024
- || Clinical, Journal: Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. (Pubmed Central) - Dec 23, 2019
P2
The results of the PRODIGE18 (Partenariat de Recherche en Oncologie DIGEstive) study showed a nonsignificant difference but favored continuation of bevacizumab with chemotherapy crossover for patients with wild-type RAS metastatic colorectal cancer that progressed with first-line bevacizumab plus chemotherapy. ClinicalTrials.gov identifier: NCT01442649 and clinicaltrialsregister.eu identifier: EUDRACT 2009-012942-22.
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Metastases: A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 23, 2019
P1, N=15, Active, not recruiting, Sponsor: University of Colorado, Denver
ClinicalTrials.gov identifier: NCT01442649 and clinicaltrialsregister.eu identifier: EUDRACT 2009-012942-22. Trial completion date: Nov 2019 --> Jun 2021 | Trial primary completion date: Jun 2019 --> Jun 2020
- || leucovorin calcium / Generic mfg., fluorouracil topical / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer Center. (Pubmed Central) - Dec 23, 2019
There was a modest improvement in median OS between 2006-2010 and 2011-2015 with the introduction of newer chemotherapeutic regimens. However, there has been no significant improvement in outcomes for African Americans or in short-term survival.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., Avastin (bevacizumab) / Roche
Clinical, P2 data, Journal: Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer. (Pubmed Central) - Dec 23, 2019
This study achieved a high pCR rate with favorable toxicity and postoperative complications in poor-risk locally advanced low rectal cancer. Multicenter study is warranted to evaluate this regimen.
- | leucovorin calcium / Generic mfg., methotrexate / Generic mfg.
Retrospective data, Journal: Management of caesarean scar pregnancy with high dose intravenous methotrexate infusion therapy: 10-year experience at a single tertiary centre. (Pubmed Central) - Dec 23, 2019
Caution is needed with factors associated with failure. Ensuring follow up ultrasound for live CSP and follow up β-hCG for all women with CSP is essential.
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial. (Pubmed Central) - Dec 23, 2019
Overall survival rate is the primary endpoint. Secondary endpoints are time to progression according to the modified response evaluation criteria in solid tumors (mRECIST) criteria, acute and chronic adverse events, and quality of life.
- | leucovorin calcium / Generic mfg.
Journal: Delayed Hypersensitivity Reaction to Leucovorin. (Pubmed Central) - Dec 23, 2019
Secondary endpoints are time to progression according to the modified response evaluation criteria in solid tumors (mRECIST) criteria, acute and chronic adverse events, and quality of life. No abstract available
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: Survival Benefit for Patients With Metastatic Urothelial Carcinoma Receiving Continuous Maintenance Chemotherapy. (Pubmed Central) - Dec 23, 2019
No abstract available Continuous maintenance chemotherapy targeting chemo-sensitive tumors, administered at metronomic intervals and focus on tumor microenvironment, can increase MUC survival benefits.
- | Journal: Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model. (Pubmed Central) - Dec 22, 2019
Continuous maintenance chemotherapy targeting chemo-sensitive tumors, administered at metronomic intervals and focus on tumor microenvironment, can increase MUC survival benefits. These findings suggest that the combination of trabectedin plus FOLFIRI has clinical potential for patients with CRC.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial initiation date, Metastases: Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma (clinicaltrials.gov) - Dec 22, 2019
P3, N=900, Not yet recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
These findings suggest that the combination of trabectedin plus FOLFIRI has clinical potential for patients with CRC. Initiation date: Aug 2019 --> Jun 2020
- || oxaliplatin / Generic mfg., fluorouracil / Generic mfg., Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, HEOR: Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer. (Pubmed Central) - Dec 22, 2019
P3
Sensitivity analysis showed that the cost of PFS in the cetuximab plus FOLFOX-4 arm was the most influential factor in the Markov model. The combination of cetuximab and FOLFOX-4 is not a cost-effective strategy compared with FOLFOX-4 alone for the first-line treatment of patients with RAS wt mCRC from the perspective of Chinese society.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Colorectal Liver Metastases: A Pathologist's Guide to Creating an Informative Report and Improving Patient Care. (Pubmed Central) - Dec 21, 2019
- In this review, we will describe strategies and practical approaches to maximize the information gained from CRLM resections. A checklist is provided that may be used while signing out these cases to remind pathologists of additional components they may wish to include in their reports to best guide patient management.
- | leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Retrospective data, Journal: Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer. (Pubmed Central) - Dec 20, 2019
The CAPOX regimen is preferred in older patients. Disease progression, metastasis, and mortality rates are higher with FOLFOX than with CAPOX.
- || fluorouracil / Generic mfg., Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, P2 data, Journal: EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. (Pubmed Central) - Dec 20, 2019
P2
Disease progression, metastasis, and mortality rates are higher with FOLFOX than with CAPOX. Depending on the results of the INNOVATION trial, the addition of HER2 targeted treatment with either T or T and P to CT may inform future study designs or become a standard in the perioperative management HER2+ GC.
- | Cyramza (ramucirumab) / Eli Lilly
New P2 trial, Metastases: SWOG S1922: Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers (clinicaltrials.gov) - Dec 19, 2019
P2, N=94, Not yet recruiting, Sponsor: Southwest Oncology Group
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: A case report. (Pubmed Central) - Dec 19, 2019
Dose reduction of oxaliplatin is not necessarily needed if hemodialysis is performed soon after the infusion. Further studies are needed to distinguish between active and inactive oxaliplatin products during the 2nd peak of the free platinum concentration curve in this population.
- || Clinical, Retrospective data, Journal: Applicability of postoperative carcinoembryonic antigen levels in determining post-liver-resection adjuvant chemotherapy regimens for colorectal cancer hepatic metastasis. (Pubmed Central) - Dec 19, 2019
In conclusion, perioperative CEA levels are crucial in prognosis and treatment of patients with CRC hepatic metastasis after LR. Additionally, certain regimens of adjuvant chemotherapy alongside post-LR CEA levels may provide beneficial results.
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. (Pubmed Central) - Dec 19, 2019
Adjuvant fluoropyrimidine alone is the most optimal regimen for patients with high-risk stage II colon adenocarcinoma compared with the other adjuvant chemotherapy regimens. Adjuvant FOLFOX can serve as an optimal regimen for patients with pathologic stage III colon adenocarcinoma, regardless of age, sex, or tumor location.
- ||||| ensituximab (NEO-102) / ImmunityBio
Trial completion date, Trial termination, Metastases: QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer (clinicaltrials.gov) - Dec 19, 2019
P2, N=81, Terminated, Sponsor: Precision Biologics, Inc
Adjuvant FOLFOX can serve as an optimal regimen for patients with pathologic stage III colon adenocarcinoma, regardless of age, sex, or tumor location. Trial completion date: Sep 2018 --> Dec 2019 | Active, not recruiting --> Terminated; DSMB terminated the trial for futility.
- | conatumumab (AMG 655) / Amgen
Trial completion date, Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Dec 19, 2019
P2, N=12, Active, not recruiting, Sponsor: Amgen
Trial completion date: Sep 2018 --> Dec 2019 | Active, not recruiting --> Terminated; DSMB terminated the trial for futility. Trial completion date: Nov 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial suspension: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Dec 16, 2019
P2, N=136, Suspended, Sponsor: National Cancer Institute (NCI)
Trial completion date: Nov 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020 Recruiting --> Suspended
- | Avastin (bevacizumab) / Roche
Trial completion, Trial completion date, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 16, 2019
P2, N=139, Completed, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Suspended Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Nov 2019
- | Avastin (bevacizumab) / Roche
Enrollment open, Metastases: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab (clinicaltrials.gov) - Dec 15, 2019
P1, N=20, Recruiting, Sponsor: Anne Noonan
Active, not recruiting --> Completed | Trial completion date: Jun 2020 --> Nov 2019 Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly
Trial termination: Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum (clinicaltrials.gov) - Dec 13, 2019
P2, N=6, Terminated, Sponsor: University of Wisconsin, Madison
Not yet recruiting --> Recruiting Completed --> Terminated; Loss of funding
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial completion date, Trial primary completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Dec 13, 2019
P2, N=136, Recruiting, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; Loss of funding Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
- ||| leucovorin calcium / Generic mfg.
Thanks @agrothey for masters class on leucovorin. It’s important for us all to know why we do something’s a certain way rather than “that’s how I saw it done in fellowship” #crcsm (Twitter) - Dec 12, 2019
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Also, is leucovorin modulation different from higher dose 5-FU? (Twitter) - Dec 12, 2019
- || leucovorin calcium / Generic mfg.
There are numerous questions here. Is leucovorin as important in people withhigh folic acid diets as in low? As Axel pointed out, how much and with the short half-life is there potential benefit of oral LV on subsequent days? (Twitter) - Dec 12, 2019
- ||| leucovorin calcium / Generic mfg.
Clinical: Our institution includes leucovorin in the template for mFOLFIRINOX, though ever since the shortages we have used a fixed dose (single vial) of leucovorin. Frankly it feels like voodoo to include in this regimen 🤷♂️. (Twitter) - Dec 12, 2019
- || leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
Clinical, Journal: Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review. (Pubmed Central) - Dec 10, 2019
Recently, CRT with leucovorin-fluorouracil-oxaliplatin (FOLFOX) has become popular due to its convenience and lower toxicity...Encephalopathy was the only reported grade 3 adverse event. Although the present study included a limited number of cases, the findings suggest that CRT with FOLFOX may be a valuable option for the treatment of patients with esophageal squamous cell cancer and synchronous rectal cancer.
- Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
A phase II study of trifluridine/tipiracil, irinotecan, and bevacizumab in pretreated metastatic colorectal cancer (TABAsCO). (Level 1, West Hall - Poster Board N9) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_1023;
P1
This study was approved and funded by the National Comprehensive Cancer Network (NCCN) Oncology Research Program from general research support provided by Taiho Oncology, Inc. Research Funding: This study was approved and funded by the National Comprehensive Cancer Network (NCCN) Oncology Research Program from general research support provided by Taiho Oncology, Inc
- proTide 5-fluorouracil (NUC-3373) / NuCana BioMed, irinotecan / Generic mfg.
NuTide: 302—A phase Ib study of the ProTide NUC-3373 in combination with standard therapies in advanced colorectal cancer. (Level 1, West Hall - Poster Board N8) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_1022;
P1
In Part 2, NUC-3373 (±LV) will be administered in dose escalating cohorts, in a modified 3+3 design, with either oxaliplatin (NUFOX) or irinotecan (NUFIRI)...Clinical trial information: NCT03428958. Research Funding: NuCana
- leucovorin calcium / Generic mfg., Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
MONARCC: A randomized phase II study of panitumumab monotherapy and panitumumab (pan) plus 5 Fluorouracil (FU) as first-line therapy for RAS and BRAF wild type metastatic colorectal cancer (mCRC): An AGITG clinical trial. (Level 1, West Hall - Poster Board N5) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_1019;
Elderly patients are not well represented in clinical trials and may be more suited to treatment protocols with lower toxicity risks; FU plus bevacizumab (bev) is commonly used...Randomisation 1:1, stratified by primary tumour side, performance status, number of metastatic sites; to pan 6mg/kg 2 weekly or panitumumab plus FU 400 mg/m² bolus; leucovorin 200mg/m²; FU 2400mg/m² 48 hour infusion 2 weekly...Clinical trial information: 12618000233224. Research Funding: AMGEN, Other Foundation
- Avastin (bevacizumab) / Roche, Modufolin (arfolitixorin) / Isofol Medical
AGENT: An open-label phase III study of arfolitixorin versus leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer. (Level 1, West Hall - Poster Board N2) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_1016;
P3
Clinical trial information: NCT03750786. Research Funding: Isofol Medical AB (publ)
- Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment. (Level 1, West Hall - Poster Board N1) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_1015;
P2
Based on these, a reduced dose of CAP and IRI regimen in combination with Oxaliplatin (OX) and BEV, CAPOXIRI+BEV may be more feasible than FOLFOXIRI+BEV, without compromising efficacy...Pts are randomized to either the recommended dose of CAPOXIRI+BEV or FOLFOXIRI+BEV (OX: 85 mg/m2, IRI: 165 mg/m2, l-leucovorin: 200 mg/m2, 5-FU: 3200 mg/m2), with the strata of RAS/BRAF status, previous adjuvant OX, tumor sidedness, and UGT1A1 status...Clinical trial information: NCT04097444. Research Funding: Chugai pharmaceutical co., ltd
- onvansertib (PCM-075) / TrovaGene, Avastin (bevacizumab) / Roche, irinotecan / Generic mfg.
A phase Ib/II study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second-line treatment of metastatic colorectal cancer (mCRC) in patients with a KRAS mutation. (Level 1, West Hall - Poster Board M21) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_1013;
P1b/2
Clinical trial information: NCT03829410. Research Funding: Trovagene
- leucovorin calcium / Generic mfg.
The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: A multicenter retrospective analysis. (Level 1, West Hall - Poster Board M4) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_996;
Oxaliplatin DI of > 80% is associated with improved OS in patients receiving chemotherapy for high risk stage II and stage III CC. Research Funding: None
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
The potential in artificial intelligence-driven radiomic signature to predict survival in patients with metastatic colorectal cancer treated with cetuximab-based therapy. (Level 1, West Hall - Poster Board M3) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_995;
P3
The signature provided early prediction of sensitivity and survival and could be used to guide treatment continuation decisions. Research Funding: Merck KgaA, Other Foundation